Who are Daunorubicin/Idarubicin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ADM, Idarubicin(IDA), idarubicin, etoposide, cytarbine, teniposide, Doxorubicin hydrochloride liposome, Liposomal daunorubicin, treatment Doxorubicin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/daunorubicin-idarubicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Daunorubicin/Idarubicin — Competitive Intelligence Brief

Daunorubicin/Idarubicin (Daunorubicin/Idarubicin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthracycline chemotherapy agent. Area: Oncology.

phase 3 Anthracycline chemotherapy agent Topoisomerase II; DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Daunorubicin/Idarubicin (Daunorubicin/Idarubicin) — Institute of Hematology & Blood Diseases Hospital, China. Daunorubicin and idarubicin are anthracycline chemotherapy agents that intercalate into DNA and inhibit topoisomerase II, leading to DNA strand breaks and cancer cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Daunorubicin/Idarubicin TARGET	Daunorubicin/Idarubicin	Institute of Hematology & Blood Diseases Hospital, China	phase 3	Anthracycline chemotherapy agent	Topoisomerase II; DNA
ADM	ADM	Italian Sarcoma Group	marketed	Anthracycline chemotherapy agent	Topoisomerase II; DNA
Idarubicin(IDA)	Idarubicin(IDA)	Chinese Academy of Medical Sciences	marketed	Anthracycline topoisomerase II inhibitor	Topoisomerase II; DNA
idarubicin, etoposide, cytarbine, teniposide	idarubicin, etoposide, cytarbine, teniposide	St. Jude Children's Research Hospital	phase 3	Combination chemotherapy regimen (topoisomerase II inhibitors and nucleoside analog)	Topoisomerase II; DNA synthesis
Doxorubicin hydrochloride liposome	Doxorubicin hydrochloride liposome	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	marketed	Anthracycline chemotherapy agent (liposomal formulation)	DNA topoisomerase II
Liposomal daunorubicin	Liposomal daunorubicin	University of Birmingham	phase 3	Anthracycline chemotherapy agent	Topoisomerase II, DNA
treatment Doxorubicin	treatment Doxorubicin	Assistance Publique Hopitaux De Marseille	phase 3	Anthracycline chemotherapy agent	DNA (intercalating agent); Topoisomerase II

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anthracycline chemotherapy agent class)

Assistance Publique Hopitaux De Marseille · 1 drug in this class
Institute of Hematology & Blood Diseases Hospital, China · 1 drug in this class
Italian Sarcoma Group · 1 drug in this class
University of Birmingham · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Daunorubicin/Idarubicin — Competitive Intelligence Brief. https://druglandscape.com/ci/daunorubicin-idarubicin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab